Evidence map›Paper›PMID 40162000›Full record

ArticleTherapeutic advances in medical oncology2025

Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with

Timothée Vigié, Alexandre Perrier, Brice Chanez, Julien De Martino, Loëtitia Favre, Florence Coulet, Jean-Baptiste Bachet, Erell Guillerm, Léo Mas

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Timothée VigiéHepato-Gastroenterology and Digestive Oncology Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France.ORCID https://orcid.org/0009-0007-0239-0136
Alexandre PerrierGenetics Medical Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France.
Brice ChanezMedical Oncology Department, Institut Paoli-Calmettes, Marseille, France.
Julien De MartinoDepartment of Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, Sorbonne University, AP-HP, Pitié Salpêtrière Hospital, Paris, France.
Loëtitia FavreGenetics Medical Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France.
Florence CouletGenetics Medical Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France.
Jean-Baptiste BachetHepato-Gastroenterology and Digestive Oncology Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France.
Erell GuillermGenetics Medical Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France.
Léo MasHepato-Gastroenterology and Digestive Oncology Department, Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, 47-83 Boulevard de l'Hôpital, Paris 75013, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a rising cause of cancer death. Therapeutic options are scarce and of limited efficacy. Up to 26% of patients with metastatic pancreatic cancer could benefit from targeted therapies. We report here for the first time the case of three patients with metastatic pancreatic ductal adenocarcinoma (PDAC) without

Indexed as

case reportctDNAEGFRexon 19 deletionKRAS wild typeliquid biopsyNGSosimertinibpancreatic cancerpancreatic ductal adenocarcinoma

Identifiers

PMID40162000
PMCPMC11954516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.